


ENETS

EUROPEAN
NEUROENDOCRINE
TUMOR SOCIETY

24th Annual Conference

10-12 March 2027

MILAN, Italy



24th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
10 – 12 March 2027

Abstract Guidelines

Contents

1.	Call for abstracts	3
2.	Key dates	3
3.	Scientific scope and eligibility.....	3
4.	Scientific categories.....	4
5.	Trials-in-progress / Trial concepts.....	4
6.	Encore abstracts and previously presented abstracts.....	5
7.	ENETS abstracts as encores for other conferences	5
8.	Late-breaking abstracts	5
9.	Submission roles and requirements.....	6
9.1.	Abstract submitter	6
9.2.	Industry support.....	7
9.3.	Authors.....	7
9.4.	Presenting author	7
10.	Ethical and regulatory requirements.....	7
11.	Abstract format and content	8
12.	Industry-supported abstracts	9
13.	Use of generative artificial intelligence	9
14.	Presentation types.....	9
14.1.	Oral abstract presentations.....	10
14.2.	Mini oral presentations.....	10
14.3.	Poster stage presentations.....	10
14.4.	Physical poster exhibition	10
14.5.	ePoster exhibition	10
15.	Submission status and notifications	10
16.	Abstract editing and changes after submission.....	10
17.	Abstract withdrawal	11
18.	Intellectual property and publication rights.....	11
18.1.	Accepted abstracts.....	11
18.2.	ePosters and ePoster videos	12
18.3.	Warranties, third-party rights and personal data	12
19.	Confidentiality policy.....	12
20.	Governing law and place of jurisdiction	12
21.	Questions or queries	13

1. Call for abstracts

The **European Neuroendocrine Tumor Society (ENETS)** welcomes submissions of new, ongoing and updated research in neuroendocrine tumours for presentation at the **24th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease (ENETS 2027)**.

All accepted abstracts will be published on the ENETS website and included in the ENETS ePoster Gallery. Abstracts from all categories, except case reports and trials-in-progress/trial concepts, may also be selected for oral abstract, mini oral, poster stage or physical poster presentation at ENETS 2027.

All accepted abstracts will be published in the form submitted, subject to any editorial, formatting or other permitted adjustments described in these guidelines.

All accepted abstracts, except case reports and trials-in-progress/trial concepts, will also be included in a supplement of *The Journal of Neuroendocrinology (JNE)*.

2. Key dates

- | | |
|---|---|
| ➤ Abstract submission: | 15 September–5 November 2026 (23:59 CET) |
| ➤ Late-breaking abstract final data deadline: | 10 December 2026 (23:59 CET) |
| ➤ Abstract acceptance notifications: | mid-December 2026 |
| ➤ Abstract withdrawal deadline: | 5 January 2027 |
| ➤ Abstract editing deadline: | 5 January 2027 |
| ➤ Presentation format notifications: | mid-January 2027 |

All abstracts – including preliminary late-breaking abstracts – must be submitted via the online tool by the general abstract submission deadline. ENETS will not accept any submissions via email, post, or fax.

Final data for late-breaking abstracts must be sent by email to the ENETS Office at office@enets.org.

3. Scientific scope and eligibility

Abstracts submitted to ENETS must be relevant to neuroendocrine neoplasms (NENs).

ENETS welcomes well-designed clinical, translational and basic research, including retrospective, registry and real-world-data studies.

Retrospective registry and descriptive real-world-data studies are eligible for submission only if the study design and methodology are appropriate to address a clearly defined scientific question. Purely descriptive analyses or basic comparisons without a clear scientific rationale, appropriate methodology or meaningful interpretation are generally not considered suitable for submission.

ENETS reserves the right to reject abstracts that do not meet these requirements.

4. Scientific categories

Authors must select one topic category that best fits the subject of their abstract. Categories include:

1. Basic science
2. Clinical science
 - Epidemiology including registries
 - Clinical pathology
 - Clinical biomarkers
 - Imaging & nuclear medicine: diagnosis and therapeutic
 - Medical treatment
 - Surgical topics
 - Other
3. Case reports
4. Trials-in-progress / Trial concepts
5. Nursing and allied health topics

For abstracts related to clinical trials within the subcategories **Imaging & nuclear medicine: diagnosis and therapeutic**, **Medical treatment** and **Surgical topics**, please indicate whether the data are derived from a completed clinical trial. Providing this information upfront will assist in the review process and in the selection of abstracts for oral and poster presentations.

5. Trials-in-progress / Trial concepts

Abstracts in this category are intended to present **ongoing** or **upcoming clinical trials**.

The purpose is to describe the study design, including the patient population, study objectives, treatment strategy and methodology, without reporting actual study data or results.

Trials-in-progress / trial concepts may include:

- Study objectives
- Inclusion/exclusion criteria
- Trial design, e.g. randomisation or blinding
- Methodology
- Anticipated timelines
- Trial registration number, if applicable

They must not include:

- Preliminary data
- Trial results
- Conclusions based on trial results

For example, a statement such as “*The trial showed a significant improvement in XYZ*” would not be appropriate for a trials-in-progress/ trial concept abstract.

If results are available, please submit the abstract under the appropriate scientific category.

6. Encore abstracts and previously presented abstracts

Abstracts submitted to ENETS should generally represent original work.

Encore abstracts that do not contain meaningful new scientific content will not be accepted. ENETS does not accept abstracts that are identical to abstracts previously submitted to or presented at other international scientific meetings.

This restriction does not apply to abstracts previously presented only at smaller regional or national meetings.

Conferences organised by NANETS, ESMO, ASCO and comparable organisations are considered international scientific meetings.

If an abstract has previously been submitted to or presented at an international scientific conference, the version submitted to ENETS must include meaningful new scientific content. This may include:

- New data
- A new analysis or subanalysis
- A new study endpoint
- A meaningful update to the study or project timeline
- Other substantive new findings

Minor editorial changes or rewording alone do not constitute new scientific content.

7. ENETS abstracts as encores for other conferences

Abstracts accepted by ENETS for the ENETS conference and subsequently published as citable abstracts in the *Journal of Neuroendocrinology (JNE)* supplement may not subsequently be submitted as encore abstracts to other international scientific meetings.

Abstracts accepted by ENETS for presentation at the ENETS Annual Conference may also be submitted to national or regional meetings, provided that the same abstract is not published separately in another journal or conference supplement or assigned an individual DOI.

8. Late-breaking abstracts

ENETS welcomes late-breaking abstracts that present high-quality, new research findings from prospective, interventional, practice-changing clinical trials.

The late-breaking abstract deadline is not an extension of the general abstract submission deadline. All late-breaking abstracts must first be submitted through the online submission portal by the general abstract submission deadline.

To facilitate a smooth submission process, please follow the steps below:

- (1) Submit a preliminary abstract by the general abstract submission deadline**, indicating the data expected to become available by the late-breaking abstract deadline.

The preliminary abstract must include:

- Clinical trial title
- Trial registration number
- Background
- Methods
- Expected results
- Expected conclusions

- (2) Send the abstract submission confirmation** to the [ENETS Office](#) and indicate that the submission is intended for consideration as a late-breaking abstract.

- (3) Send the final results or data** to the [ENETS Office](#) by the late-breaking abstract deadline of 10 December 2026.

The Abstract Reviewing Committee will review the preliminary abstract and will determine whether it qualifies for consideration as a late-breaking abstract.

Following receipt and review of the final results/data, the Committee will also determine whether the abstract is selected for oral abstract, mini oral, poster stage or physical poster presentation at ENETS 2027. Please note that ENETS cannot guarantee outcomes of either decision in advance.

9. Submission roles and requirements

Please read the following requirements carefully before submitting your abstract. Abstracts that do not comply with these guidelines may be rejected.

9.1. Abstract submitter

The abstract submitter is the person who submits the abstract and serves as the main contact during the submission process. The abstract submitter may, but does not have to, be one of the authors.

The abstract submitter is responsible for:

- confirming that all authors have consented to the submission and that all necessary institutional approvals or clearances have been obtained;
 - ensuring that all co-authors are aware of and support the content of the abstract;
 - ensuring that a presenting author who meets the ENETS presenter requirements is designated;
 - maintaining accurate and up-to-date contact information for the submission; and
-

- completing all required disclosure information.

Further requirements relating to ethical approval, informed consent and patient confidentiality are set out in the [section Ethical and regulatory requirements](#).

9.2. Industry support

During the online submission process, the submitter must indicate whether the abstract is industry-supported using the relevant Yes/No option.

9.3. Authors

Provide the required author and affiliation information for all authors in the online submission portal.

An individual may be listed as first author on more than one abstract.

Academic degrees are not required.

9.4. Presenting author

The presenting author is the person designated to present the abstract if it is selected for oral abstract, mini oral, poster stage or physical poster presentation.

The presenting author may be one of the listed authors or another designated presenter. A valid email address must be provided for the presenting author.

The presenting author must not be employed by a pharmaceutical company or other relevant industry organisation. Authors employed by such organisations may nevertheless be listed as authors. Further information is provided in the [section Industry-supported abstracts](#).

10. Ethical and regulatory requirements

Authors are responsible for ensuring that the research described in their abstract complies with all applicable ethical, legal and regulatory requirements.

Where required, appropriate ethical and institutional approval and informed consent must be obtained.

Authors must protect patient confidentiality and must not include information from which an individual patient could reasonably be identified without appropriate consent.

For case reports, authors are responsible for obtaining informed consent for publication where required by applicable laws, regulations or institutional policies.

ENETS may request additional information regarding ethical approval, informed consent or other relevant approvals.

11. Abstract format and content

Please ensure that your abstract complies with the following format and content requirements.

Abstract title

Use capital and lowercase letters.

Example: *Role of interleukins in hypothalamic neuroinflammation*

Affiliation

Provide the institution name, location and country for each affiliation. More than one affiliation may be entered. Do not include postcodes.

Example: *Department of Psychology, University of North Carolina, Chapel Hill, USA*

Structure

Organise the abstract according to the following five sections, which correspond to the fields in the online submission form:

- **Introduction/Background:** A short introduction indicating the rationale of the study.
- **Aims:** Clearly outline the aim and goals of the study.
- **Material and Methods:** Brief description of the methodological procedures.
- **Results:** A summary of the research results.
- **Conclusions:** A statement of the main conclusion(s).

Content

Clearly describe the objectives and, where applicable, the results of the research in the abstract.

Character limit

Abstracts must not exceed 2,500 characters, including spaces and excluding the headings provided in the online submission form.

The system will alert you if you exceed the limit.

Character requirements

Abstracts must be written using the Latin alphabet. Common diacritics, special characters and scientific symbols, including Greek letters used as scientific notation (e.g. α , β , μ), are permitted. Text written in other scripts cannot be accepted.

Tables

No tables or spreadsheets will be accepted.

Proofreading

Ensure that the abstract is free of language and content errors.

The ENETS Abstract Reviewing Committee reserves the right to correct the title format and/or typos in the abstract.

12. Industry-supported abstracts

Industry-supported abstracts are eligible for submission. However, sponsor names, promotional or advertising materials, and company logos must not be identifiable on the poster or presentation. Any mention of the sponsoring company or company logos will be replaced with the term **“industry-sponsored”**. This policy applies to all publications, including those online and in the abstract booklet, as well as to posters and ePosters presented during the conference and uploaded to the poster gallery afterwards. This measure is required to comply with UEMS-EACCME regulations and to ensure that CME accreditation is not compromised.

Individuals employed by a pharmaceutical company or other relevant industry organisation may be listed as authors but are not eligible to present an abstract. If an abstract is selected for presentation and the proposed presenter is employed by such an organisation, an alternative presenter who meets the ENETS presenter requirements must be appointed.

This restriction applies to all four presentation types:

- oral abstract presentation;
- mini oral presentation;
- poster stage presentation; and
- physical poster exhibition.

The restriction does not apply to the ePoster exhibition, as this is an exhibition rather than a presentation.

13. Use of generative artificial intelligence

Generative artificial intelligence (AI) tools may be used to assist with language, grammar, editing or drafting of an abstract.

Authors remain fully responsible for the scientific content, accuracy, originality and integrity of the abstract, including any content generated or modified using AI tools.

Generative AI tools must not be listed as authors.

Authors must ensure that the use of AI tools does not compromise the confidentiality of unpublished research, patient information or other confidential information.

14. Presentation types

Accepted abstracts may be selected for different presentation formats at ENETS 2027, depending on scientific quality, originality and suitability for the respective format. All accepted abstracts will also be included in the ePoster exhibition.

14.1. Oral abstract presentations

Authors of superior-quality abstracts with original data will be invited to present during a session in the scientific programme.

Authors invited to present an oral abstract are not eligible for mini oral prizes.

14.2. Mini oral presentations

Authors of high-quality abstracts with original data will be invited to present during a mini oral session.

Authors invited to present a mini oral abstract are not eligible for oral abstract prizes.

14.3. Poster stage presentations

Authors of high-quality abstracts will be invited to present their abstracts during a poster stage session in the scientific programme.

14.4. Physical poster exhibition

A **pre-selected group of accepted abstracts** will be invited to participate in the physical poster exhibition at MiCo Milano Convention Centre, Milan, Italy.

14.5. ePoster exhibition

All accepted abstracts will be invited to upload an ePoster for the ePoster exhibition. ePosters will be available for viewing on dedicated terminals and ePoster stands onsite at the conference.

Please note: Case reports and Trials-in-progress / Trial concepts are eligible for the ePoster exhibition but are not eligible for ENETS abstract prizes.

15. Submission status and notifications

The abstract submitter will receive a confirmation email once the abstract has been successfully submitted.

Acceptance notifications will be sent to the presenting author by mid-December 2026.

Notifications regarding selection for oral abstract, mini oral, poster stage or physical poster presentation will be sent to the presenting author by mid-January 2027.

16. Abstract editing and changes after submission

Minor changes to an abstract may be made until the abstract editing deadline. To edit a submitted abstract, please request an edit link by contacting the ENETS Office at office@enets.org. Please do not resubmit the abstract.

Minor changes may include correction of typographical errors and amendments to author names, affiliations or other author information.

Substantive changes to the scientific content of the abstract are not permitted after the abstract submission deadline.

Changes made after completion of the review process will not be considered by the reviewers and will not affect the outcome of the review.

17. Abstract withdrawal

To withdraw an abstract, the submitter must submit a request to the ENETS Office at office@enets.org before the withdrawal deadline.

Withdrawal requests after this date will be reviewed on a case-by-case basis.

18. Intellectual property and publication rights

18.1. Accepted abstracts

By submitting an abstract, the submitter confirms that all authors have consented to the submission and that they have the necessary authority to agree to the intellectual property and publication terms on behalf of all authors.

Upon acceptance of an abstract, the authors grant ENETS an exclusive, worldwide, perpetual and unrestricted right to use the accepted abstract, including the right to reproduce, publish, distribute, store, archive, communicate and make it available to the public in electronic, print or any other format, and the right to grant sublicences to and transfer such rights. This grant is made free of charge.

Accepted abstracts may in particular be made available through ENETS publications and platforms, including, without limitation:

- the abstract supplement of the *Journal of Neuroendocrinology*, which is published open access;
- the ENETS conference abstract book;
- the ENETS conference app and myENETS;
- the ENETS website and the ENETS conference website; and
- any publicly accessible abstract database on ENETS.org and ENETSconference.org and any future ENETS publications, platforms or services.

ENETS may also publish the title, author names, affiliations and other information submitted with the abstract in connection with the abstract and its publication.

ENETS may make editorial and formatting corrections that do not alter the scientific content of the abstract, and may make the adjustments required under the [section Industry-supported abstracts](#).

The authors retain the right to use the abstract themselves for non-commercial scientific, teaching and archiving purposes, provided that the ENETS conference is credited as the place of first publication.

18.2. ePosters and ePoster videos

By uploading an ePoster or ePoster video, the authors grant ENETS a non-exclusive, worldwide, perpetual licence to host, store, archive, reproduce, transcode and adapt to the extent technically necessary, display and make available the ePoster or ePoster video through the ENETS conference app, the ePoster gallery and myENETS, including the right to grant sublicences to service providers acting on behalf of ENETS. This licence is not limited to the conference period.

ENETS will make ePosters and ePoster videos available to conference attendees only.

ENETS does not acquire ownership of, or any exclusive rights in, the ePosters or ePoster videos. Any request by a third party to use, reuse or reproduce an ePoster or ePoster video must be addressed to the authors directly; ENETS does not grant such permissions and does not act as an intermediary.

Where an ePoster or ePoster video incorporates an accepted abstract, or any part of it, [section 18.1](#) applies to the abstract content, while [section 18.2](#) applies to the ePoster or ePoster video as a whole.

18.3. Warranties, third-party rights and personal data

The authors warrant that they hold all rights required to grant the rights under [sections 18.1](#) and [18.2](#), that the submitted abstract does not infringe any third-party rights, and that any third-party material used has been cleared. The authors indemnify ENETS against third-party claims arising from a breach of this warranty. ENETS may remove content in the event of a suspected infringement.

19. Confidentiality policy

Abstracts submitted to ENETS will be treated as confidential during the submission and review process and will remain under embargo until officially released by ENETS.

Authors must not publicly distribute or publish the submitted ENETS abstract, or disclose information regarding its review or acceptance status where subject to embargo, before the applicable ENETS release date.

This embargo does not prevent presentation of the underlying research at national or regional meetings where permitted under [Sections 6](#) and [7](#).

20. Governing law and place of jurisdiction

These guidelines and the rights granted under them are governed by German law, excluding the UN Convention on Contracts for the International Sale of Goods. The exclusive place of jurisdiction is Berlin, Germany, to the extent permitted by law.

21. Questions or queries

If you have questions or queries about your abstract or the abstract guidelines for ENETS 2027, please do not hesitate to contact us at office@enets.org.

Best regards,
ENETS Office